Sino Biopharm and Sanofi Sign $1.53 Billion Oncology Licensing Deal

A subsidiary of Hong Kong-listed Sino Biopharmaceutical has entered into an exclusive global licensing agreement with French pharmaceutical giant Sanofi. The deal, valued at up to $1.53 billion, focuses on a specialized blood cancer treatment that recently received regulatory approval in China. Under the terms of the agreement, Sanofi will gain the rights to develop and commercialize the drug on a global scale. This partnership represents a significant milestone for Sino Biopharm, providing a substantial capital injection and validating its research and development capabilities. For Sanofi, the acquisition strengthens its oncology pipeline and expands its presence in the competitive cancer treatment market. Market analysts view the move as a strategic win for both companies, potentially driving long-term growth in the healthcare sector.